The role of regorafenib in metastatic colorectal cancer
Mené en Asie sur 204 patients atteints d'un cancer colorectal métastatique réfractaire, cet essai de phase III évalue l'efficacité, du point de vue de la survie globale, et la toxicité du regorafénib (durée médiane de suivi : 7,4 mois)
During the past decade, the prognosis of patients with metastatic colorectal cancer has substantially improved because of the availability of many active drugs against this disease and their strategic use within the continuum of care. Within these options, anti-angiogenic treatment has been shown to be effective as a component of first-line and second-line treatment, even when continued beyond tumor progression.
The Lancet Oncology , commentaire, 2014